Chinook Therapeutics Valuation

Chinook Therapeutics Investor Information

About 97.0% of the company shares are owned by institutional investors. The book value of Chinook Therapeutics was now reported as 5.32. The company recorded a loss per share of 3.24. Chinook Therapeutics last dividend was issued on the 2nd of October 2020. The entity had 1:5 split on the 2nd of October 2020. Based on the key indicators related to Chinook Therapeutics' liquidity, profitability, solvency, and operating efficiency, Chinook Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.

Chinook Therapeutics Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Chinook Therapeutics has an asset utilization ratio of 1.07 percent. This suggests that the Company is making $0.0107 for each dollar of assets. An increasing asset utilization means that Chinook Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.

Chinook Therapeutics Ownership Allocation

Chinook Therapeutics holds a total of 67.05 Million outstanding shares. The majority of Chinook Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Chinook Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Chinook Therapeutics. Please pay attention to any change in the institutional holdings of Chinook Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Chinook Therapeutics Profitability Analysis

The company reported the previous year's revenue of 6.13 M. Net Loss for the year was (187.87 M) with loss before overhead, payroll, taxes, and interest of (135.08 M).

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.

Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.